Pre-emptive Abdominal Aortic Aneurysm Sac Embolization During EVAR
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05575570 |
Recruitment Status :
Not yet recruiting
First Posted : October 12, 2022
Last Update Posted : October 12, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Abdominal Aortic Aneurysm Without Rupture | Device: EVAR | Not Applicable |
In all 100 patients will be included, 50 in each group. i The first group with pre-emptive AAA sac embolization during EVAR and the control group consisted of 50 patients without pre-emptive AAA sac embolization and EVAR.
The primary goal is to investigate if the pre-emptive embolization can reduce the endoleak incidence and AAA shrinkage. Further, to investigate all secondary interventions during the follow-up and any difference between groups and correlation if any with pre-emptive embolization.
Demographic, comorbidities, antiplatelet and anticoagulation drugs, AAA characteristics, patent lumbal and inferior mesenteric artery, intervention characteristics and follow-up data will be recorded and analysed.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Pre-emptive Abdominal Aortic Aneurysm Sac Embolization During Endovascular Abdominal Aortic Repair for Infrarenal Abdominal Aortic Aneurysm - Randomized Study |
Estimated Study Start Date : | January 1, 2023 |
Estimated Primary Completion Date : | January 1, 2025 |
Estimated Study Completion Date : | January 1, 2026 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Pre-emptive AAA sac embolization |
Device: EVAR
EVAR stent graft and embolization material CE marked. |
Sham Comparator: No pre-emtive AAA sac embolization |
Device: EVAR
EVAR stent graft and embolization material CE marked. |
- Endoleak type 2 incidence, on control CT and ultrasound scanning. Further aneurysm sac regression [ Time Frame: 3 years ]Incidence of endoleak type 2 and other endoleak will be noted and analysed. Sac regression comparing the baseline CT aorta scanning and AAA diameter in mm, with control CT or ultrasound scanning.
- AAA diameter, measurement on control and/or ultrasound [ Time Frame: 3 years ]
- Secondary interventions, endovascular secondary interventions( additional embolization, a new stent graft deployment etc) [ Time Frame: 3 years ]The type of secondary interventions, incidence, time to secondary intervention, and the outcome will be recorded and analysed.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 100 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient with 55mm (male) or 50 mm (female) AAA, available for EVAR
- > 18 year old
Exclusion Criteria:
- Not accept to participate
- Ruptured AAA
- Outside for instruction for the use EVAR
Responsible Party: | Stevo Duvnjak, Principal investigator, Rigshospitalet, Denmark |
ClinicalTrials.gov Identifier: | NCT05575570 |
Other Study ID Numbers: |
H-22000209 |
First Posted: | October 12, 2022 Key Record Dates |
Last Update Posted: | October 12, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
AAA Embolization Endoleak sac regression |
Aneurysm Aortic Aneurysm Aortic Aneurysm, Abdominal Rupture |
Vascular Diseases Cardiovascular Diseases Aortic Diseases Wounds and Injuries |